Participant flow

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer · Source last updated 2026-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   400 mg sorafenib by mouth twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.

   id

   FG000

   title

   Sorafenib Alone

2. description

   27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib by mouth twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib by mouth twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.

   id

   FG001

   title

   SBRT Followed by Sorafenib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         11

      type

      Protocol Violation

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         97

      2. group Id

         FG001

         num Subjects

         96

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         92

      2. group Id

         FG001

         num Subjects

         85

      type

      Eligible Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         88

      2. group Id

         FG001

         num Subjects

         83

      comment

      Eligible, started treatment, and were assessed for adverse events.

      type

      Adverse Event Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         46

      2. group Id

         FG001

         num Subjects

         37

      comment

      Eligible with consent for quality of life study component

      type

      Quality of Life Population

   5. achievements

      1. group Id

         FG000

         num Subjects

         92

      2. group Id

         FG001

         num Subjects

         85

      comment

      Participants contributing data to results are considered to have completed the study.

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice